Lu Wenping, Dong Jiahong, Huang Zhiqiang, Guo Deyu, Liu Yousheng, Shi Shuang
Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing, China.
J Gastroenterol Hepatol. 2008 Dec;23(12):1874-8. doi: 10.1111/j.1440-1746.2008.05527.x.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. However, there is no general consensus as to which staging system is the most reliable for predicting the survival of patients with HCC. The aims of this study were to compare commonly-used staging systems in a cohort of Chinese HCC patients undergoing curative resection.
From January 1991 to June 2002, 234 Chinese patients undergoing curative resection for HCC from one medical center were evaluated. All patients were classified by the Okuda, Cancer of the Liver Italian Program (CLIP), tumor node metastasis (TNM) (6th edition) and the Chinese University Prognostic Index (CUPI) staging systems. Survival curves were calculated using the Kaplan-Meier method and were examined using log-rank testing. The overall predictive power for patient survival with each staging system was evaluated by the area under the receiver operating characteristic (ROC) curve.
The overall median survival of the entire cohort was 24.9 months (95% confidence interval (CI) 18.15-31.65 months) and the estimated survival rates at 1, 3, and 5 years were 69.66% 3.01%, 41.02% 3.31%, and 29.08% 3.55%, respectively. In our patient cohort, the log-rank test demonstrated that the TNM and Okuda staging systems gave better results than the other staging systems in the prognosis stratification. The prognostic predictive powers of the TNM staging for survival, evaluated by ROC curve areas, was also superior.
For HCC patients undergoing curative resection, the TNM staging system (6th edition) proved the best for prognostic stratification and prognosis prediction.
肝细胞癌(HCC)是全球最常见的癌症之一。然而,对于哪种分期系统最能可靠地预测HCC患者的生存率,目前尚无普遍共识。本研究的目的是比较在中国一组接受根治性切除的HCC患者中常用的分期系统。
对1991年1月至2002年6月期间在某医疗中心接受HCC根治性切除的234例中国患者进行评估。所有患者均按照奥田、意大利肝癌计划(CLIP)、肿瘤淋巴结转移(TNM)(第6版)和中国大学预后指数(CUPI)分期系统进行分类。采用Kaplan-Meier方法计算生存曲线,并使用对数秩检验进行检验。通过受试者操作特征(ROC)曲线下面积评估每个分期系统对患者生存的总体预测能力。
整个队列的总体中位生存期为24.9个月(95%置信区间(CI)18.15 - 31.65个月),1年、3年和5年的估计生存率分别为69.66%±3.01%、41.02%±3.31%和29.08%±3.55%。在我们的患者队列中,对数秩检验表明,TNM和奥田分期系统在预后分层方面比其他分期系统给出了更好的结果。通过ROC曲线面积评估,TNM分期对生存的预后预测能力也更优。
对于接受根治性切除的HCC患者,TNM分期系统(第6版)被证明在预后分层和预后预测方面是最佳的。